Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of AI R&D Tool for Patient Stratification - Mechanism of Action Evaluation in Triple Negative Breast Cancer (PEAR-MET)

NCT06182306 is registered in ClinicalTrials.gov with Ourotech, Inc. as lead sponsor.

NCT NCT06182306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06182306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of AI R&D Tool for Patient Stratification - Mechanism of Action Evaluation in Triple Negative Breast Cancer (PEAR-MET)
Lead sponsor
Ourotech, Inc.
Phase
Observational
Overall status
Unknown status
Start date
April 30, 2024
Completion date
June 30, 2026
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, triple negative breast cancer